Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00079612 · ClinicalTrials.gov registry record · Phase 2
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 501
- Enrollment target
NCT00079612 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 501 participants.
The verdict
NCT00079612, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 501 participants
- Enrollment target
Study Summary
The purpose of the study is to: * Find out if BAY 43-9006 prevents the growth of tumors * For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. * Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY 43-9006 (sorafenib) in the treatment of advanced refractory cancers. * Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some patients.
Interventions
- DRUG Placebo
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2002-09 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00079612
The ClinicalTrials.gov registry entry for NCT00079612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00079612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00079612 about?
NCT00079612 is a clinical study titled "Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer". The purpose of the study is to: * Find out if BAY 43-9006 prevents the growth of tumors * For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at that time. * Find out how long the e...
What is the current status of trial NCT00079612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 501 participants. The study started on 2002-09. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00079612?
The interventions under investigation include: Placebo (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00079612?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.